30 closest matches · ranked by relevance
Burkitt Lymphoma · Diffuse Large B-cell Lymphoma, c-MYC Positive · Plasmablastic Lymphoma
Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants
Leukemia · Lymphoma
Primary: Complete Response Rate — 83 percentage of participants
Lymphoma
Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr
Burkitt's Lymphoma · Burkitt'S-like Lymphoma
Primary: Complete Remission Rate: Percentage of Participants With Complete Remission (CR) — 85 percentage of participants
Leukemia · Lymphoma
Primary: Overall Response Rate — 11; 2 Participants
Lymphoma
Primary: Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen — 100; 100; 100; 100 percentage of patients
AIDS-Related Burkitt Lymphoma · Atypical Burkitt/Burkitt-Like Lymphoma · High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Primary: Participants With a Response — 9 Participants
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Lymphoma
Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Classical Hodgkin Lymphoma · Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 0.05 Proportion of participants
Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Diffuse Large B Cell Lymphoma
Primary: Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications — 4; 1; 3 Participants
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Lymphoma
Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Lymphoma
Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
Low-grade B Cell Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
Lymphoma
Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability